76 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of phenoxyindazoles and phenylthioindazoles as ROR¿ inverse agonists.
Galderma R & D
Brain penetrant liver X receptor (LXR) modulators based on a 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole core.
Vitae Pharmaceuticals
Discovery of a 2-hydroxyacetophenone derivative as an outstanding linker to enhance potency andß-selectivity of liver X receptor agonist.
Kowa
Discovery of a Novel, Orally Efficacious Liver X Receptor (LXR)ß Agonist.
Vitae Pharmaceuticals
Identification and in Vivo Evaluation of Liver X Receptorß-Selective Agonists for the Potential Treatment of Alzheimer's Disease.
Wuxi Apptec
Altered activity profile of a tertiary silanol analog of multi-targeting nuclear receptor modulator T0901317.
The University Of Tokyo
Styrylphenylphthalimides as Novel Transrepression-Selective Liver X Receptor (LXR) Modulators.
The University Of Tokyo
Discovery and structure-guided optimization of tert-butyl 6-(phenoxymethyl)-3-(trifluoromethyl)benzoates as liver X receptor agonists.
Daiichi Sankyo Rd Novare
Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonists.
Genentech
Design, synthesis and pharmacology of 1,1-bistrifluoromethylcarbinol derivatives as liver X receptorß-selective agonists.
Kowa
Design and discovery of 2-oxochromene derivatives as liver X receptorß-selective agonists.
Kowa
Reduction in lipophilicity improved the solubility, plasma-protein binding, and permeability of tertiary sulfonamide RORc inverse agonists.
Genentech
Modulators of the nuclear receptor retinoic acid receptor-related orphan receptor-¿ (ROR¿ or RORc).
Genentech
Liver X receptor (LXR) partial agonists: biaryl pyrazoles and imidazoles displaying a preference for LXRß.
Bristol-Myers Squibb
Liver x receptor agonists for the treatment of coronary heart disease and other disorders.
Therachem Research Medilab (India)
Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORß and ROR¿t.
Phenex Pharmaceuticals
Structure-activity relationship-guided development of retinoic acid receptor-related orphan receptor gamma (ROR¿)-selective inverse agonists with a phenanthridin-6(5H)-one skeleton from a liver X receptor ligand.
The University Of Tokyo
Structure-based design of substituted hexafluoroisopropanol-arylsulfonamides as modulators of RORc.
Genentech
Cyanidin, a natural flavonoid, is an agonistic ligand for liver X receptor alpha and beta and reduces cellular lipid accumulation in macrophages and hepatocytes.
Korea University
Induction of ABCA1 and ABCG1 expression by the liver X receptor modulator cineole in macrophages.
Korea University
Discovery of tertiary sulfonamides as potent liver X receptor antagonists.
Glaxosmithkline
Ethyl 2,4,6-trihydroxybenzoate is an agonistic ligand for liver X receptor that induces cholesterol efflux from macrophages without affecting lipid accumulation in HepG2 cells.
Korea University
Design, synthesis, and biological evaluation of novel transrepression-selective liver X receptor (LXR) ligands with 5,11-dihydro-5-methyl-11-methylene-6H-dibenz[b,e]azepin-6-one skeleton.
The University Of Tokyo
Identification of diaryl ether-based ligands for estrogen-related receptora as potential antidiabetic agents.
Johnson & Johnson Pharmaceutical Research And Development
3-(3-Aryloxyaryl)imidazo[1,2-a]pyridine sulfones as liver X receptor agonists.
Wyeth Pharmaceuticals
Discovery and development of dimeric podocarpic acid leads as potent agonists of liver X receptor with HDL cholesterol raising activity in mice and hamsters.
Merck Research Laboratories
Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists.
Phenex Pharmaceuticals
Synthesis of 4-(3-biaryl)quinoline sulfones as potent liver X receptor agonists.
Wyeth Pharmaceuticals
Identification of phenylsulfone-substituted quinoxaline (WYE-672) as a tissue selective liver X-receptor (LXR) agonist.
Wyeth Pharmaceuticals
1-(3-Aryloxyaryl)benzimidazole sulfones are liver X receptor agonists.
Wyeth Pharmaceuticals
Quinoline-3-carboxamide containing sulfones as liver X receptor (LXR) agonists with binding selectivity for LXRbeta and low blood-brain penetration.
Wyeth Pharmaceuticals
4-(3-Aryloxyaryl)quinoline sulfones are potent liver X receptor agonists.
Wyeth Pharmaceuticals
The discovery of tertiary-amine LXR agonists with potent cholesterol efflux activity in macrophages.
Glaxosmithkline
Separation of alpha-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LXRalpha-selective antagonists.
The University Of Tokyo
Discovery and SAR of cinnolines/quinolines as liver X receptor (LXR) agonists with binding selectivity for LXRbeta.
Wyeth Research
Liver X receptor agonists with selectivity for LXRbeta; N-aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropionamides.
Astrazeneca R&D SöDertäLje
Structure-guided design of N-phenyl tertiary amines as transrepression-selective liver X receptor modulators with anti-inflammatory activity.
Glaxosmithkline
Anthrabenzoxocinones from Streptomyces sp. as liver X receptor ligands and antibacterial agents.
Merck Research Laboratories
Diterpenoid, steroid, and triterpenoid agonists of liver X receptors from diversified terrestrial plants and marine sources.
Merck Research Laboratories
Guttiferone I, a new prenylated benzophenone from Garcinia humilis as a liver X receptor ligand.
Merck Research Laboratories
Carboxylic acid based quinolines as liver X receptor modulators that have LXRbeta receptor binding selectivity.
Wyeth Pharmaceuticals
Liver X receptor antagonists with a phthalimide skeleton derived from thalidomide-related glucosidase inhibitors.
University Of Tokyo
Synthesis and evaluation of anilinohexafluoroisopropanols as activators/modulators of LXRalpha and beta.
F. Hoffmann-La Roche
Design, synthesis, and structure-activity relationship of podocarpic acid amides as liver X receptor agonists for potential treatment of atherosclerosis.
Merck Research Laboratories
Discovery of a potent orally bioavailable retinoic acid receptor-related orphan receptor-gamma-t (ROR?t) inhibitor, S18-000003.
Shionogi
Recent Advances in the Medicinal Chemistry of Liver X Receptors.
Saint Louis University School Of Medicine
Structural development of tetrachlorophthalimides as liver X receptor ? (LXR?)-selective agonists with improved aqueous solubility.
The University Of Tokyo
Identification of bicyclic hexafluoroisopropyl alcohol sulfonamides as retinoic acid receptor-related orphan receptor gamma (ROR?/RORc) inverse agonists. Employing structure-based drug design to improve pregnane X receptor (PXR) selectivity.
Bristol-Myers Squibb
Novel Nonsteroidal Progesterone Receptor (PR) Antagonists with a Phenanthridinone Skeleton.
The University Of Tokyo
Indazole-based ligands for estrogen-related receptor ? as potential anti-diabetic agents.
Janssen Research And Development
DrugBank screening revealed alitretinoin and bexarotene as liver X receptor modulators.
Goethe-University Frankfurt
Side-Chain Modified Ergosterol and Stigmasterol Derivatives as Liver X Receptor Agonists.
Universit£
The role of a novel auxiliary pocket in bacterial phenylalanyl-tRNA synthetase druggability.
Astrazeneca R&D Boston
Digoxin derivatives with enhanced selectivity for the a2 isoform of Na,K-ATPase: effects on intraocular pressure in rabbits.
Weizmann Institute Of Science
Two amino acid residues confer different binding affinities of Abelson family kinase SRC homology 2 domains for phosphorylated cortactin.
Yale University
Bisubstrate inhibitors of the enzyme catechol O-methyltransferase (COMT): efficient inhibition despite the lack of a nitro group.
Laboratorium FÜR Organische Chemie
Species orthologs of the alpha-2A adrenergic receptor: the pharmacological properties of the bovine and rat receptors differ from the human and porcine receptors.
University Of Nebraska
Pharmacological profile of (R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo- 5-phenyl-1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo.
Yamanouchi Pharmaceutical